LP3 Network Free Webinar - Veterinary Compounding, A Customized Approach

Download in electronic PDF format for $25



Search the Complete Journal Archives

In Vitro Transdermal Delivery and Stability of Liposome-Encapsulated Prostaglandin E1

Author(s):  Foldvari Marianna, Oguejifor Cosmas

Issue:  Mar/Apr 1999 - Compounding for Men's Health
View All Articles in Issue

Abstract:  The aim of this study was to encapsulate prostaglandin E1 (PGE1) in liposomes, to determine the transdermal flux characteristics in vitro and to evaluate the stability of prostaglandin E1 (PGE1) in these novel transdermal delivery systems. A sensitive, reversed-phase, isocratic high-performance liquid chromatography assay of PGE1 and its major degradation products in solution, liposomes, and other topical dosage forms was developed. The effect of formulation variables – vehicle type, drug concentration, drug/lipid ratio, apparent encapsulation efficiency and pH – on transdermal drug delivery was assessed using the in vitro flow-through diffusion cell technique. The steadystate transdermal flux from the various liposomal formulations ranged from 0.01 to 0.787 (µg/cm2/hour-1) depending on the composition. Compared to the optimum liposome formulation, a conventional nonliposomal PGE1 formulation yielded a steady-state flux of 0.04 µg/cm2/hour-1. Lipid content and the apparent encapsulation efficiency correlated positively with transdermal delivery of PGE1 from liposomes. The stabilization of PGE1 by liposomes depended on the lipid composition, pH of the formulation, and storage temperature but was independent of the drug concentration. It is proposed that a stable transdermal liposomal PGE1 product, which can deliver therapeutic amounts of PGE1 in vivo, may be feasible.

Related Keywords: prostaglandin E1, PGE1, liposomes, drug/lipid ratio

Related Categories: DERMATOLOGY, HRT, PEER-REVIEWED

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
In Vitro Transdermal Delivery and Stability of Liposome-Encapsulated Prostaglandin E1 Foldvari Marianna, Oguejifor Cosmas Mar/Apr 1999 160-163 Buy
Five Compounds for Treating Diabetes-Related Conditions Meece Jerry May/Jun 2003 170 Buy
Prostaglandin E1/Papaverine HCl/Phentolamine Mesylate Injection Meece Jerry May/Jun 2003 171 Buy
Prostaglandin E1/Papaverine HCl/Phentolamine Mesylate Injection Allen Loyd V Jr Mar/Apr 1999 134 Buy
A New High-Performance Liquid Chromatographic Method for Fludarabine and Fludarabine Phosphate Compounded in Liposomes Abang Anthony M, Abbas S Ali, Pham Trinh, Lambros Maria Polikandritou Jul/Aug 2001 320-322 Buy
Does Your Drug Expertise Include Clinical Pharmaceutics? Newton David W May/Jun 2016 202-206 Buy
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse Williams LaVonn A Nov/Dec 2011 526-527 Buy
Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Lyon Joanna Nov/Dec 2012 456-460 Buy
Drugs Banned for Use in Food Animals: An Explanation Davidson Gigi S Mar/Apr 2001 101 Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample